Indra Bhattacharya has more than eight years of experience in high-value IP disputes across a range of industry sectors, including pharmaceuticals, biotechnology, medical devices, and consumer technology and electronics. He is also experienced in commercial IP matters and in technology-rich corporate transactions.
Indra has acted for some of world's leading pharmaceutical and medical device companies, including Abbott, Actavis, Celgene, and Merck in multijurisdictional high-profile patent disputes in the United Kingdom, Asia, and Australia. He is part of the Firm's award winning life sciences practice and regularly acts in transactions in the pharmaceutical field and advises on freedom to operate issues. He also has acted on trademark, design rights, and breach of confidence cases in the technology and retail sectors. He is experienced litigating before English and Australian courts.
In addition, he has significant regulatory experience having spent time in-house in pharmaceutical and research institutions. This includes pharmaceutical and medical devices regulation along with food safety and hygiene issues. He also regularly assists clients on investigations with regulators including the EMA and MHRA.
Indra holds a first class degree in law and is technically qualified with a degree in genetics and biochemistry. He has previously lectured on intellectual property law.
Guidance for European MA Holders to Prepare for Brexit, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
Senators Urge the Administration to Certify Imports of Prescription Drugs from Canada, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
New French Decree Clarifies the Scope of Biomedical Research, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
EU Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
EMA Green Lights New EudraVigilance System for Adverse Reactions, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
- September 30, 2015
Approach to '2nd Medical Use' Claims Varies Across EU, Law 360
- University of Melbourne (Graduate Diploma in Intellectual Property 2009); University of Adelaide (LL.B. with first class honours 2004; B.S. in Genetics & Biochemistry 2004)
- Solicitor of the Senior Courts of England and Wales and legal practitioner of the Supreme Courts of New South Wales, Western Australia, and Victoria and the Australian Federal Courts